Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures gain on tech rebound, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil gains after Trump says US will hit Iran 'very hard tonight'
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
Pfizer (PFE) Enters Collaboration Agreement with CytoReason
January 7, 2019 8:06 AM ESTCytoReason announced today that it has entered into a collaboration agreement with Pfizer Inc. (NYSE: PFE) that will leverage CytoReasons cell-centered models of the immune system.
CytoReason will receive from Pfizer payments potentially equaling up to low double digit millions of US$ for technology access fees, research support and certain success-based payments.
CytoReasons... More
Biogen (BIIB) Reports Strategic Collaboration with Skyhawk Therapeutics to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
January 4, 2019 7:32 AM ESTBiogen Inc (NASDAQ: BIIB) and Skyhawk Therapeutics, Inc. today announced a strategic collaboration in which the companies will leverage Skyhawks SkySTAR technology platform with the goal of discovering innovative small molecule treatments for... More
Biogen (BIIB) Reports Strategic Collaboration with C4 Therapeutics to Discover and Develop Potential New Treatments for Neurological Conditions
January 4, 2019 7:31 AM ESTBiogen Inc (NASDAQ: BIIB) and C4 Therapeutics (C4T) announced today that they have entered into a strategic collaboration to investigate the use of C4Ts novel protein degradation platform to discover and develop potential new treatments for neurological conditions,... More
Leerink Partners Downgrades Celgene (CELG) to Market Perform Following Acquisition
January 3, 2019 11:56 AM ESTLeerink Partners analyst Geoffrey Porges downgraded Celgene (NASDAQ: CELG) from Outperform to Market Perform with a price target of $102.00 (from $112.00) following acquisition.
For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.
Shares of Celgene closed at $66.64 yesterday.
... MoreBristol-Myers Squibb (BMY) Announces $5B Accelerated Share Repurchase Program
January 3, 2019 7:12 AM ESTWith news it will acquire Celgene, Bristol-Myers Squibb (NYSE: BMY) also said expects to execute an accelerated share repurchase program of up to approximately $5 billion, subject to the closing of the transaction, market conditions and Board approval.
... More